These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34323124)

  • 1. The prognostic and predictive impact of
    Park R; Lopes L; Lee S; Riano I; Saeed A
    Future Oncol; 2021 Nov; 17(31):4221-4231. PubMed ID: 34323124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
    Sahin IH; Goyal S; Pumpalova Y; Sonbol MB; Das S; Haraldsdottir S; Ahn D; Ciombor KK; Chen Z; Draper A; Berlin J; Bekaii-Saab T; Lesinski GB; El-Rayes BF; Wu C
    Oncologist; 2021 Aug; 26(8):668-675. PubMed ID: 33631043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of microsatellite instability in colorectal cancer patients.
    Micu BV; Andercou O; Vesa SC; Micu CM; Pop TR; Constantea N
    Ann Ital Chir; 2017; 6():425-432. PubMed ID: 28874631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.
    Tan E; Whiting J; Xie H; Imanirad I; Carballido E; Felder S; Frakes J; Mo Q; Walko C; Permuth JB; Sommerer K; Kim R; Anaya DA; Fleming JB; Sahin IH
    Oncologist; 2022 Mar; 27(3):191-197. PubMed ID: 35274712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.
    Wang J; Yi Y; Xiao Y; Dong L; Liang L; Teng L; Ying JM; Lu T; Liu Y; Guan Y; Pang J; Zhou L; Lu J; Zhang Z; Liu X; Liang X; Zeng X; Yi X; Zhou W; Xia X; Yang L; Zhang J; Kopetz S; Futreal PA; Wu H; Liang Z
    Mod Pathol; 2019 Jul; 32(7):1053-1064. PubMed ID: 30723297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.
    Amaki-Takao M; Yamaguchi T; Natsume S; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Miyaki M
    Oncology; 2016; 91(3):162-70. PubMed ID: 27404270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
    Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of metastatic colorectal cancer with synchronous
    Cheng Y; Fang XF; Hu HG; Wang J; Sun LF; Yuan Y
    Immunotherapy; 2020 Mar; 12(4):229-234. PubMed ID: 32172642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival.
    Batur S; Vuralli Bakkaloglu D; Kepil N; Erdamar S
    Bosn J Basic Med Sci; 2016 Nov; 16(4):254-260. PubMed ID: 27131021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
    Colle R; Lonardi S; Cachanado M; Overman MJ; Elez E; Fakih M; Corti F; Jayachandran P; Svrcek M; Dardenne A; Cervantes B; Duval A; Cohen R; Pietrantonio F; André T
    Oncologist; 2023 Sep; 28(9):771-779. PubMed ID: 37023721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
    Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
    Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer.
    Waldmann E; Ferlitsch M; Binder N; Sellner F; Karner J; Heinisch B; Klimpfinger M; Trauner M
    Digestion; 2015; 91(4):286-93. PubMed ID: 25924923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.
    Sun C; España S; Buges C; Layos L; Hierro C; Manzano JL
    Clin Colorectal Cancer; 2022 Jun; 21(2):71-79. PubMed ID: 35277355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.